Scarica l'app Stockscreener
3.13
0.63%
-0.02
Pre-mercato:
3.01
-0.12
-3.83%
Precedente Chiudi:
$3.15
Aprire:
$3.28
Volume 24 ore:
15,048
Relative Volume:
0.02
Capitalizzazione di mercato:
$2.03M
Reddito:
$104.00K
Utile/perdita netta:
$-8.39M
Rapporto P/E:
-0.0301
EPS:
-103.9477
Flusso di cassa netto:
$-8.31M
1 W Prestazione:
-17.63%
1M Prestazione:
-10.06%
6M Prestazione:
-83.78%
1 anno Prestazione:
-95.15%
Intervallo 1D:
$3.06
$3.28
Intervallo di 1 settimana:
$3.0501
$3.84
Portata 52W:
$2.86
$96.50
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Nome
Biodexa Pharmaceuticals Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare BDRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
3.13 | 2.04M | 104.00K | -8.39M | -8.31M | -103.95 |
VRTX
Vertex Pharmaceuticals Inc
|
434.31 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
630.30 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.77 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.30 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.30 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-08 | Iniziato | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Borsa (BDRX) Ultime notizie
BDRX Stock Price, Quote & Chart | BIODEXA PHARMACEUTICALS-ADR (NASDAQ:BDRX) - ChartMill
Biodexa proposes share capital reorganization at June meeting - Investing.com UK
Biodexa proposes share capital reorganization at June meeting By Investing.com - Investing.com Nigeria
Biodexa plans to shrink 373B shares without cutting ADS stakes - Stock Titan
BDRX Stock Jumps As Biodexa ADRs Lead Biotech Rally - StocksToTrade
BDRX Stock Jumps As ADR Momentum Attracts Active Traders - timothysykes.com
Biodexa Pharmaceuticals surges on pre-market trading - Intellectia AI
BDRX - Finviz
Inventory turnover of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Net income before discontinued operations of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Book value per share of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Biodexa Pharmaceuticals plc Sponsored ADR Cash Flow – FWB:5MP2 - TradingView — Track All Markets
Net debt of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Basic earnings per share (basic EPS) of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Price to earnings ratio of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Who's Buying or Selling Biodexa Pharmaceuticals PLC (STU:5MP2) Stock Today? - GuruFocus
Biodexa Pharmaceuticals Plc: Shareholders Board Members Managers and Company Profile | US59564R8723 - marketscreener.com
Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today? - Sahm
Why is Biodexa Pharmaceuticals (BDRX) stock skyrocketing today? - MSN
Biodexa partners with Syngene for MTX240 manufacturing By Investing.com - Investing.com Australia
171.7M Ordinary Shares resale prospectus — Biodexa (NASDAQ: BDRX) - Stock Titan
109.8M Ordinary Shares resale prospectus — Biodexa (NASDAQ: BDRX) - stocktitan.net
943.4M Ordinary Shares for Resale; Biodexa (NASDAQ: BDRX) resale filing - stocktitan.net
1.7018B shares for resale by holders — Biodexa (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADS for resale via equity line - Stock Titan
Biodexa’s eRapa Program: Global Expansion and European Gains - StocksToTrade
Biodexa partners with Syngene for MTX240 manufacturing - Investing.com
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies - ChartMill
BDRX SEC FilingsBiodexa Pharmaceuticals plc 10-K, 10-Q, 8-K Forms - Stock Titan
No approved FAP drug: Biodexa opens global eRapa access - Stock Titan
[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADSs for resale under equity line - Stock Titan
943.4M Ordinary Shares resale by selling holders (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (BDRX) flags going-concern doubts amid ongoing losses - Stock Titan
Biodexa (NASDAQ: BDRX) grows pipeline but warns on 2026 funding needs - stocktitan.net
Preliminary Results for the Year Ended 31 December 2025 - GlobeNewswire
Biodexa releases audited preliminary 2025 results for investors - Stock Titan
Biodexa partners with Tanner Pharma for FAP drug early access By Investing.com - Investing.com Australia
Biodexa Launches Global Early Access Program for eRapa for - GlobeNewswire
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group - markets.businessinsider.com
Biodexa partners with Tanner Pharma for FAP drug early access - Investing.com
Biodexa (NASDAQ: BDRX) director reports detailed stock option holdings - stocktitan.net
Biodexa Pharmaceuticals changes ADR ratio to meet Nasdaq rules By Investing.com - Investing.com Australia
Biodexa Pharmaceuticals announces ADR ratio change - MSN
Biodexa Pharmaceuticals Announces Reverse ADR Split to Support Nasdaq Compliance - tipranks.com
Biodexa Pharmaceuticals (BDRX) Announces ADR Ratio Change - GuruFocus
Biodexa Pharmaceuticals changes ADR ratio to meet Nasdaq rules - Investing.com
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change to Comply with Nasdaq Minimum Bid Price Requirement - Quiver Quantitative
Reverse ADR split at Biodexa (Nasdaq: BDRX) targets Nasdaq $1 bid rule - Stock Titan
ADR Ratio Change - Bitget
Biodexa Pharmaceuticals (NASDAQ: BDRX) director lists stock option position - Stock Titan
Biodexa Pharmaceuticals Plc Adr Azioni (BDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.19%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):